Advancing peptides for the treatment of rare endocrine and metabolic disorders
We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
PROGRAMS
AZP-3601
Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.
AZP-3601 (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.
AZP-3813
AZP-3813 is a highly potent, macrocyclic peptide growth hormone (GH) receptor antagonist in development as a potential treatment for acromegaly.
HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.
AZP-3404
AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.
LEADERSHIP
Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.
Press Releases & Recent News
Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
Download a PDF copy of this press release: EN FR Company to host key opinion leader webinar today, October 1, …
Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone …